A Phase 1, Multicenter, Open-Label Study Of Bms-986403 In Subjects With Relapsed And/Or Refractory Chronic Lymphocytic Leukemia (Cll) Or Small Lymphocytic Lymphoma (Sll) Read more
A Phase I/II Study To Investigate The Safety And Clinical Activity Of GSK3326595 And Other Agents In Subjects With Myelodyplastic Syndrome And Acute Myeloid Leukaemia Read more
KO-539 Menin-KMT2A (MLL) inhibitor Phase ½ R/R AML with NPM1 Mutation) A Phase 1/2A First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemi Read more
A Phase 1/2, First-in-Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART) Bi-Specific Antibody-Based Molecule, in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Intermediate-2/High Risk Myelodysplastic Syndrome Read more
